Institut Bordet - Retour à la page d'accueil
en
I want to donate to research

Philippe Aftimos

Department : Medical oncology, Clinical Trials Conduct Unit (CTCU)
 
philippe.aftimos [at] bordet.be

Publications

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Authors : Pondé N, Aftimos P, Piccart-Gebhart M
Year : 2019
Journal : Curr Treat Options Oncol

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.

Authors : Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P
Year : 2019
Journal : Lancet Oncol

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Authors : Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG
Year : 2019
Journal : Future Oncol

Network science in clinical trials: A patient-centered approach.

Authors : Manem VSK, Salgado R, Aftimos P, Sotiriou C, Haibe-Kains B
Year : 2018
Journal : Semin Cancer Biol

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.

Authors : Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart-Gebhart M, Rothé F, Sotiriou C
Year : 2018
Journal : Ann Oncol

More publications »

Follow us!

Youtube

Exclusive images of the new Jules Bordet Institute!

Watch the video and discover the major project for the new Jules Bordet Institute. Magnificent images of the construction work on the   80,000 m² dedicated exclusively to cancer are accompanied by explanations on how the project was conceived to combine excellence of patient care with optimal well-being for patients and care staff.